durvalumab + gemcitabine + cisplatin

Durvalumab + gemcitabine + cisplatin is a combination therapy used primarily for the treatment of locally advanced or metastatic biliary tract cancers, including bile duct cancer and gallbladder cancer. Durvalumab is an immunotherapy drug classified as a checkpoint inhibitor (specifically, a monoclonal antibody targeting PD-L1), while both gemcitabine and cisplatin are cytotoxic chemotherapy agents. The combination works by leveraging the immune system to target cancer cells (via PD-L1 inhibition) alongside direct cytotoxic effects from chemotherapy. This regimen was approved based on clinical trial data showing improved outcomes compared to chemotherapy alone in this setting[1][5][6].

Brand names

Imfinzi

Other names

durvalumab with cisplatin and gemcitabineGC-D regimen